Overall, despite some encouraging results, the current evidence is still insufficient to determine the extent to which upregulation of immune checkpoint molecules contributes to anti-PD-1 or anti-CTLA-4 resistance in GC patients. This evidence concerns the gene CTLA4 and gastric cancer.